How artificial intelligence revolutionizes the world of multiple myeloma

• DOI: 10.3389/frhem.2024.1331109
• Publication Date: 2024-02-02T17:12:36Z
• Authors: Martha Romero; Adrián Mosquera O...; Mateo Mejía Salda...
• Keywords: multiple myeloma; 03 medical and health sciences; machine learning; 0302 clinical medicine; target therapy; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282; prognosis model; early diagnosis

Multiple myeloma is the second most frequent hematologic malignancy worldwide with high morbidity and mortality. Although it considered an incurable disease, enhanced understanding of this neoplasm has led to new treatments, which have improved patients’ life expectancy. Large amounts data been generated through different studies in settings clinical trials, prospective registries, real-world cohorts, incorporated laboratory tests, flow cytometry, molecular markers, cytogenetics, diagnostic images, therapy into routine practice. In review, we described how these can be processed analyzed using models artificial intelligence, aiming improve accuracy translate benefit, allow a substantial improvement early diagnosis response evaluation, speed up analyses, reduce labor-intensive process prone operator bias, evaluate greater number parameters that provide more precise information. Furthermore, identified intelligence allowed development integrated predict probability achieving undetectable measurable residual progression-free survival, overall survival leading better decisions, potential inform on personalized therapy, could outcomes. Overall, revolutionize multiple care, being necessary validate cohorts develop incorporate daily